Cargando…

Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations

BACKGROUND & OBJECTIVES: Accurate determination of antimicrobial resistance profiles is of great importance to formulate optimal regimens against multidrug-resistant tuberculosis (MDR-TB). Although para-aminosalicylic acid (PAS) has been widely used clinically, the reliable testing methods for P...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wei, Li, Shanshan, Ge, Qiping, Guo, Haiping, Shang, Yuanyuan, Ren, Weicong, Wang, Yufeng, Xue, Zhongtan, Lu, Jie, Pang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637297/
https://www.ncbi.nlm.nih.gov/pubmed/36335391
http://dx.doi.org/10.1186/s12941-022-00537-z
_version_ 1784825153900773376
author Wang, Wei
Li, Shanshan
Ge, Qiping
Guo, Haiping
Shang, Yuanyuan
Ren, Weicong
Wang, Yufeng
Xue, Zhongtan
Lu, Jie
Pang, Yu
author_facet Wang, Wei
Li, Shanshan
Ge, Qiping
Guo, Haiping
Shang, Yuanyuan
Ren, Weicong
Wang, Yufeng
Xue, Zhongtan
Lu, Jie
Pang, Yu
author_sort Wang, Wei
collection PubMed
description BACKGROUND & OBJECTIVES: Accurate determination of antimicrobial resistance profiles is of great importance to formulate optimal regimens against multidrug-resistant tuberculosis (MDR-TB). Although para-aminosalicylic acid (PAS) has been widely used clinically, the reliable testing methods for PAS susceptibility were not established. Herein, we aimed to establish critical test concentration for PAS on the Mycobacterial Growth Indicator Tube (MGIT) 960 in our laboratory settings. METHODS: A total of 102 clinical isolates were included in this study, including 82 wild-type and 20 resistotype isolates. Minimum inhibitory concentration (MIC) was determined by MGIT 960. Whole-genome sequencing was used to identify the mutation patterns potentially conferring PAS resistance. Sequence alignment and structure modelling were carried out to analyze potential drug-resistant mechanism of folC mutant. RESULTS: Overall, the Minimum inhibitory concentration (MIC) distribution demonstrated excellent separation between wild-type and resistotype isolates. The wild-type population were all at least 1 dilution below 4 μg/ml, and the resistotype population were no lower than 4 μg/ml, indicating that 4 μg/ml was appropriate critical concentration to separate these two populations. Of 20 mutant isolates, 12 (60.0%) harbored thyA mutations, 2 (10%) had a mutation on upstream of dfrA, and the remaining isolates had folC mutations. Overall, thyA and folC mutations were scattered throughout the whole gene without any one mutation predominating. All mutations within thyA resulted in high-level resistance to PAS (MIC > 32 μg/ml); whereas the MICs of isolates with folC mutations exhibited great diversity, ranged from 4 to > 32 μg/ml, and sequence and structure analysis partially provided the possible reasons for this diversity. CONCLUSIONS: We propose 4 μg/ml as tentative critical concentration for MGIT 960. The major mechanism of PAS resistance is mutations within thyA and folC in MTB isolations. The whole-gene deletion of thyA locus confers high-level resistance to PAS. The diversity of many distinct mutations scattered throughout the full-length folC gene challenges the PCR-based mutation analysis for PAS susceptibility.
format Online
Article
Text
id pubmed-9637297
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96372972022-11-07 Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations Wang, Wei Li, Shanshan Ge, Qiping Guo, Haiping Shang, Yuanyuan Ren, Weicong Wang, Yufeng Xue, Zhongtan Lu, Jie Pang, Yu Ann Clin Microbiol Antimicrob Research BACKGROUND & OBJECTIVES: Accurate determination of antimicrobial resistance profiles is of great importance to formulate optimal regimens against multidrug-resistant tuberculosis (MDR-TB). Although para-aminosalicylic acid (PAS) has been widely used clinically, the reliable testing methods for PAS susceptibility were not established. Herein, we aimed to establish critical test concentration for PAS on the Mycobacterial Growth Indicator Tube (MGIT) 960 in our laboratory settings. METHODS: A total of 102 clinical isolates were included in this study, including 82 wild-type and 20 resistotype isolates. Minimum inhibitory concentration (MIC) was determined by MGIT 960. Whole-genome sequencing was used to identify the mutation patterns potentially conferring PAS resistance. Sequence alignment and structure modelling were carried out to analyze potential drug-resistant mechanism of folC mutant. RESULTS: Overall, the Minimum inhibitory concentration (MIC) distribution demonstrated excellent separation between wild-type and resistotype isolates. The wild-type population were all at least 1 dilution below 4 μg/ml, and the resistotype population were no lower than 4 μg/ml, indicating that 4 μg/ml was appropriate critical concentration to separate these two populations. Of 20 mutant isolates, 12 (60.0%) harbored thyA mutations, 2 (10%) had a mutation on upstream of dfrA, and the remaining isolates had folC mutations. Overall, thyA and folC mutations were scattered throughout the whole gene without any one mutation predominating. All mutations within thyA resulted in high-level resistance to PAS (MIC > 32 μg/ml); whereas the MICs of isolates with folC mutations exhibited great diversity, ranged from 4 to > 32 μg/ml, and sequence and structure analysis partially provided the possible reasons for this diversity. CONCLUSIONS: We propose 4 μg/ml as tentative critical concentration for MGIT 960. The major mechanism of PAS resistance is mutations within thyA and folC in MTB isolations. The whole-gene deletion of thyA locus confers high-level resistance to PAS. The diversity of many distinct mutations scattered throughout the full-length folC gene challenges the PCR-based mutation analysis for PAS susceptibility. BioMed Central 2022-11-05 /pmc/articles/PMC9637297/ /pubmed/36335391 http://dx.doi.org/10.1186/s12941-022-00537-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Wei
Li, Shanshan
Ge, Qiping
Guo, Haiping
Shang, Yuanyuan
Ren, Weicong
Wang, Yufeng
Xue, Zhongtan
Lu, Jie
Pang, Yu
Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations
title Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations
title_full Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations
title_fullStr Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations
title_full_unstemmed Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations
title_short Determination of critical concentration for drug susceptibility testing of Mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thyA, folC and dfrA mutations
title_sort determination of critical concentration for drug susceptibility testing of mycobacterium tuberculosis against para-aminosalicylic acid with clinical isolates with thya, folc and dfra mutations
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637297/
https://www.ncbi.nlm.nih.gov/pubmed/36335391
http://dx.doi.org/10.1186/s12941-022-00537-z
work_keys_str_mv AT wangwei determinationofcriticalconcentrationfordrugsusceptibilitytestingofmycobacteriumtuberculosisagainstparaaminosalicylicacidwithclinicalisolateswiththyafolcanddframutations
AT lishanshan determinationofcriticalconcentrationfordrugsusceptibilitytestingofmycobacteriumtuberculosisagainstparaaminosalicylicacidwithclinicalisolateswiththyafolcanddframutations
AT geqiping determinationofcriticalconcentrationfordrugsusceptibilitytestingofmycobacteriumtuberculosisagainstparaaminosalicylicacidwithclinicalisolateswiththyafolcanddframutations
AT guohaiping determinationofcriticalconcentrationfordrugsusceptibilitytestingofmycobacteriumtuberculosisagainstparaaminosalicylicacidwithclinicalisolateswiththyafolcanddframutations
AT shangyuanyuan determinationofcriticalconcentrationfordrugsusceptibilitytestingofmycobacteriumtuberculosisagainstparaaminosalicylicacidwithclinicalisolateswiththyafolcanddframutations
AT renweicong determinationofcriticalconcentrationfordrugsusceptibilitytestingofmycobacteriumtuberculosisagainstparaaminosalicylicacidwithclinicalisolateswiththyafolcanddframutations
AT wangyufeng determinationofcriticalconcentrationfordrugsusceptibilitytestingofmycobacteriumtuberculosisagainstparaaminosalicylicacidwithclinicalisolateswiththyafolcanddframutations
AT xuezhongtan determinationofcriticalconcentrationfordrugsusceptibilitytestingofmycobacteriumtuberculosisagainstparaaminosalicylicacidwithclinicalisolateswiththyafolcanddframutations
AT lujie determinationofcriticalconcentrationfordrugsusceptibilitytestingofmycobacteriumtuberculosisagainstparaaminosalicylicacidwithclinicalisolateswiththyafolcanddframutations
AT pangyu determinationofcriticalconcentrationfordrugsusceptibilitytestingofmycobacteriumtuberculosisagainstparaaminosalicylicacidwithclinicalisolateswiththyafolcanddframutations